Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | BRD4 | O60885 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR7 | P34969 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468193 | 0.90 | ALDH1A1 (0.64) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| SCHEMBL16245152 | 0.90 | ALDH1A1 (0.64) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| SCHEMBL557776 | 0.84 | KDM4E (0.70) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| SCHEMBL16801499 | 0.84 | KDM4E (0.73) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| SCHEMBL4056419 | 0.84 | HSD11B1 (0.54) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| SCHEMBL4051581 | 0.84 | DRD2 (0.64) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| Hydrochloric Acid SCHEMBL1703924 | 0.83 | KDM4E (0.68) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| SCHEMBL5705098 | 0.83 | KDM4E (1.00) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| SCHEMBL16802119 | 0.83 | KDM4E (0.71) | ALDH1A1KDM4EBRD4POLBCREBBP | |
| SCHEMBL3231094 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4EBRD4POLBCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082802-B1 | TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE | IOMET PHARMA LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| WO-2015082499-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2015-06-11 | — | — | WO | disclosed |
| US-7560471-B2 | 5-{4-[1-(2-Ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid; histamine H1 antagonists; bronchial dialtors; asthma; allergic rhinitis; conjunctivitis; dermatitis; urticaria; selective antiallergic effects so less side effect reduction and lower dosage | LABORATORIOS ALMIRALL S.A. (ES) | 2009-07-14 | — | — | US | disclosed |
| US-7560471-B2 | 5-{4-[1-(2-Ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid; histamine H1 antagonists; bronchial dialtors; asthma; allergic rhinitis; conjunctivitis; dermatitis; urticaria; selective antiallergic effects so less side effect reduction and lower dosage | LABORATORIOS ALMIRALL S.A. (ES) | 2009-07-14 | — | — | US | disclosed |
| US-7560471-B2 | 5-{4-[1-(2-Ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid; histamine H1 antagonists; bronchial dialtors; asthma; allergic rhinitis; conjunctivitis; dermatitis; urticaria; selective antiallergic effects so less side effect reduction and lower dosage | LABORATORIOS ALMIRALL S.A. (ES) | 2009-07-14 | — | — | US | disclosed |
| US-7189741-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA S.A. (ES) | 2007-03-13 | — | — | US | disclosed |
| EP-1513826-A1 | NEW INDOLYLPIPERIDINE DERIVATIVES AS POTENT ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116471-A1 | Indolylpiperidine derivatives as antihistaminic aand antiallergic agents | ALMIRALL PRODESFARMA S.A. (ES) | 2004-06-17 | — | — | US | disclosed |
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | disclosed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | disclosed |
| WO-2003099807-A1 | NEW INDOLYLPIPERIDINE DERIVATIVES AS POTENT ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2003-12-04 | — | — | WO | disclosed |
| EP-1330453-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2003-07-30 | — | — | EP | disclosed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | disclosed |
| WO-2002036589-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2002-05-10 | — | — | WO | disclosed |
| EP-1183251-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075130-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | ALDH1A1 3981/4885KDM4E 465/4885BRD4 1542/4885 |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | ALDH1A1 356/4885KDM4E 1249/4885BRD4 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.